I-Corps - Developing of a computer-based multimodal mind and body approach for mild cognitive decline

Summary Mild cognitive impairment (MCI) represents an intermediate state between normal aging and the diagnosis of clinically probable very early Alzheimer's disease (AD). Since MCI manifests before the onset of AD, it may be the optimal stage in which to intervene with preventative therapies for AD and age-related dementia before progressive neurological loss and irreversible cognitive impairment. Nevertheless, pharmacologic treatment for MCI is far from satisfactory, highlighting the urgent need for new treatment solutions for MCI. Baduanjin (BDJ) is a unique and innovative mind-body exercise characterized by the interplay of symmetrical physical postures and movements, focusing on strengthening muscles and tendons. It consists of eight simple movements that can be easily practiced at home when guided by videos /audio. These characteristics make it a suitable option for older adults with MCI. Studies from both our group and others have demonstrated its potentials for improving cognitive function for older adults with MCI. Nevertheless, studies also showed that the response to BDJ varies significantly, some individuals demonstrate only a moderate response. To overcome the challenge, this application aims to integrate BDJ with other mind and body approaches to develop a more effective treatment option for MCI. The goal of this Phase I R41 (STTR) application is to develop a computer-based multimodal mind and body approach (cbMMBA) to improve the cognitive function for MCI. Specifically, we will first develop a functional cbMMBA platform (prototype) integrating BDJ, acupressure, and relaxation techniques (Aim 1). We chose these methods, not only because some of these methods alone have demonstrated their potential to improve cognitive function in MCI / dementia, but because they also can interact with each other positively to produce synergistic effects. Next, we will perform a feasibility study using the cbMMBA on MCI (Aim 2). This application, if successful, will provide a cost-effective and easily accessible treatment option for MCI and other age-related dementia, significantly improve the prevention of MCI development, and directly benefit patients suffering from the highly prevalent disorder, particularly for those who may have limited access to in- person mind and body interventions.